# DIAL: HCP commentary report

> 29 verified statements (9 from clinicians verified by NPI or staff page) from 15 commentary sources · 6 findings · updated Oct 28, 2026

## Report

- Trial: A Phase II-III Randomized Trial Evaluating Maintenance Pembrolizumab (± Pemetrexed) Until Progression Versus Observation (± Pemetrexed) After 6 Months of Platinum-based Doublet Chemotherapy Plus Pembrolizumab Induction Treatment in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)
- NCT ID: NCT05255302
- Registry: https://clinicaltrials.gov/study/NCT05255302
- Sponsor: Intergroupe Francophone de Cancerologie Thoracique
- Phase: Phase 2/Phase 3
- Status: Recruiting
- Drugs: pemetrexed
- Version: v1.0.0, edition 1
- Accepted: 2026-10-28
- Last checked: 2026-10-28
- Release hash: 4c1d9d2673b25e9566998f57ea6ae3f06a1ccb46d3f9067bdaa15124085e9f81

## Counts

- HCP commentary sources screened: 95
- Sources cited by verified statements: 16
- Verified statements: 29
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 9
- Findings: 6
- People found in screened sources: 12
- Voices cited: 12
- Cited voices identity-verified: 11
- Organisational or shared accounts (not counted as people): 5

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

DIAL asks whether to stop or continue pembrolizumab after six months of first-line chemoimmunotherapy in controlled metastatic NSCLC. Clinicians in the sources reviewed express enthusiasm for shorter treatment, while acceptance of a stopping strategy remains conditional. The prospect of less toxicity is welcomed; survival evidence draws scrutiny. Patient selection and biomarker-guided duration remain open questions. The sources reviewed for this edition place DIAL's main results at ESMO 2026.

## Open Medical Affairs question

What evidence and patient-selection criteria would justify stopping pembrolizumab at six months without treating early survival similarity as proven equivalence?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. Encouraging phase II findings are explicitly distinguished from established safety or non-inferiority
- F2. The favorable reading combines similar reported survival with less toxicity
- F3. Patient selection and biomarker-guided duration remain open questions
- F4. Practical enthusiasm includes a consequential mischaracterization of the duration question
- F5. Finite-course arguments support the question, but do not resolve the six-month threshold
- F6. Academic de-escalation is valued, with DICIPLE treated as precedent rather than a DIAL outcome

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 7 | 4 | 4 | 3 | none recorded | 2 |
| F2 | 10 | 5 | 5 | 4 | recorded | 3 |
| F3 | 3 | 3 | 3 | 3 | none recorded | 2 |
| F4 | 3 | 3 | 3 | 1 | none recorded | 3 |
| F5 | 6 | 5 | 3 | 5 | none recorded | 3 |
| F6 | 5 | 4 | 3 | 3 | none recorded | 3 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 4 | 2 | 0 | 0 | 1 | 7 | 0 | 4 posts and articles | yes |
| F2 | 5 | 1 | 0 | 3 | 1 | 10 | 0 | 5 posts and articles | yes |
| F3 | 2 | 1 | 0 | 0 | 0 | 3 | 0 | 3 posts and articles | yes |
| F4 | 1 | 0 | 0 | 1 | 1 | 3 | 0 | 2 posts and articles, 1 registry | yes |
| F5 | 3 | 1 | 0 | 1 | 1 | 6 | 1 | 3 posts and articles | yes |
| F6 | 4 | 0 | 0 | 0 | 1 | 5 | 1 | 3 posts and articles | yes |

### Trial dimensions

- Primary endpoint: Phase II: 18-month overall survival (OS): F1 (2 shared claims), F2 (3 shared claims)
- Primary endpoint: Phase III: overall survival: no finding draws on it directly
- Secondary endpoints: F1 (2 shared claims), F2 (5 shared claims)
- Population and setting: F1 (2 shared claims), F2 (3 shared claims), F3 (1 shared claims)
- The comparison: F1 (3 shared claims), F2 (4 shared claims), F3 (1 shared claims), F4 (1 shared claims), F6 (1 shared claims)
- Safety and tolerability: F1 (2 shared claims), F2 (5 shared claims)
- Design and conduct: F1 (5 shared claims), F2 (5 shared claims)

## Sample findings

Paraphrased; the full report links each statement to its source.

### F1. Encouraging phase II findings are explicitly distinguished from established safety or non-inferiority

An X post asks what level of certainty DIAL provides for the treatment-duration decision.

Source: X thread, 2026-10-25.

### F3. Patient selection and biomarker-guided duration remain open questions

An X post raises DIAL's question of whether immunotherapy can be stopped safely after six months.

Source: X thread, 2026-10-21.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 6 | Titles free |
| Detailed analysis | 7 sections | Paid |
| Verified statements with short source quotes and links | 29 | Paid |
| Trial aspects mapped | 11 | Free |
| Sources with links | 16 | Counts free |
| Speaker attribution for cited voices | 12 | Paid |

## Trial aspects

10 discussed · 1 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Phase II: 18-month overall survival (OS) | discussed | 3 | 2 |
| Primary endpoint: Phase III: overall survival | no commentary found | 0 | 0 |
| Secondary endpoints | discussed | 5 | 4 |
| Population and setting | discussed | 5 | 3 |
| The comparison | discussed | 9 | 7 |
| Safety and tolerability | discussed | 5 | 4 |
| Design and conduct | discussed | 5 | 4 |
| Patient selection, response and biomarker-guided duration | discussed | 2 | 2 |
| Finite treatment, late recurrence and the two-year threshold | discussed | 5 | 3 |
| Academic de-escalation rationale and DICIPLE precedent | discussed | 5 | 3 |
| Practical treatment-intensity framing alongside PERSEE | discussed | 2 | 2 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 80 | 15 |
| YouTube | 6 | 0 |
| Bluesky threads | 5 | 0 |
| Podcasts | 3 | 0 |
| X videos | 1 | 0 |
| Registry (primary source, cited for context) | not screened | 1 |

- Screened window: 2016-02-06 to 2026-10-26
- Cited window: 2023-06-04 to 2026-10-25
- Retrieved: 2026-10-28

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Phase II-III Randomized Trial Evaluating Maintenance Pembrolizumab (± Pemetrexed) Until Progression Versus Observation (± Pemetrexed) After 6 Months of Platinum-based Doublet Chemotherapy Plus Pembrolizumab Induction Treatment in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)
- Registry: NCT05255302 (https://clinicaltrials.gov/study/NCT05255302)
- Study IDs: IFCT-2103 · 2021-006044-27
- Sponsor: Intergroupe Francophone de Cancerologie Thoracique
- Design: Phase 2/Phase 3 · interventional, randomized, parallel, phase2, phase3
- Status: Recruiting
- Enrollment: 1,360 (estimated)
- Start: 2022-05-02 (actual)
- Primary completion: 2025-05 (estimated)
- Primary endpoint: Phase II: 18-month overall survival (OS) (18 months after inclusion)
- Primary endpoint: Phase III: overall survival (about 24 months after randomization)
- Intervention: Pembrolizumab before randomization (drug)
- Intervention: Chemotherapy (drug)
- Intervention: Pemetrexed (drug)
- Intervention: Pembrolizumab after randomization (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- 1 matching source (1 podcast) could not be read and is not included.
- For 1 recording, a transcript separated by speaker was not available, so quotes come from the original automatic transcript and may lack speaker labels.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 32 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
- The report represents only the sources reviewed for this edition. Reposts, organizational or account-level posts, and reports of talks do not establish a count of independent HCP endorsements or a consensus.
- Searches emphasized trial identifiers and names; unnamed references, short acronyms and transcription variants may be missing, including discussion of the same clinical question without the DIAL name.
- One podcast was unavailable, additional checking of a video transcript was unsuccessful, and four potentially relevant social-media passages were not fully assessed. Additional views or qualifications may therefore be absent.
- No DIAL results publication was available among the reviewed sources, and no separate protocol was listed in the registry material. Numerical phase II findings are presented as authors' reports rather than conclusions from a reviewed trial results publication.
- The cited safety summaries use different adverse-event categories and values. Their denominators, grades and statistical uncertainty are not available in the statements cited, so the figures should not be pooled or treated as interchangeable.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- Comments span posts dated 2023–2026 and different events. Post dates are not session dates and do not demonstrate changes in an author's position.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-10-28: current edition

Last checked for new commentary 2026-10-28. No corrections. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Focused (29 verified statements)
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $1,300
- 6 months of weekly updates: $1,900
- 12 months of weekly updates: $2,600
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (11 now), at most $750; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/dial-nct05255302
- Agents: POST https://www.erudio.com/api/orders with {"report": "dial-nct05255302", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=dial-05255302

## Cite

Erudio Health. DIAL (NCT05255302): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 28, 2026. https://www.erudio.com/reports/dial-nct05255302

## Machine access

- JSON: https://www.erudio.com/reports/dial-nct05255302.json
- Markdown: https://www.erudio.com/reports/dial-nct05255302.md
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "dial-05255302"}`